GPP
IMCR icon

Great Point Partners’s Immunocore IMCR Stock Holding History

Great Point Partners’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-115,000
Closed -$7.47M – 37
2024
Q1 		$7.47M Sell
115,000
-178,000
-61% -$12.2M 1.17% 28
2023
Q4 		$20M Buy
293,000
+2,083
+0.7% +$108K 3.41% 13
2023
Q3 		$15.1M Sell
290,917
-6,165
-2% -$365K 2.75% 15
2023
Q2 		$17.8M Buy
297,082
+41,715
+16% +$2.38M 3.49% 13
2023
Q1 		$12.6M Buy
+255,367
New +$14.4M 2.48% 18
2022
Q4 		– Sell
-78,527
Closed -$3.69M – 47
2022
Q3 		$3.69M Buy
+78,527
New +$3.74M 0.89% 29

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Great Point Partners's IMCR Position: Q2 2024 in Review

Great Point Partners sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 115,000 shares — an estimated $7.47M sold.

Great Point Partners first reported a position in IMCR in Q3 2022 and held it in 6 quarters. The position peaked at $20M in Q4 2023. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • Great Point Partners reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • Great Point Partners sold 115,000 Immunocore shares in Q2 2024, an estimated $7.47M.
  • Great Point Partners first reported a position in Immunocore in Q3 2022 and held it in 6 quarters.
  • Great Point Partners's Immunocore position peaked at $20M in Q4 2023.
  • 138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Great Point Partners's 13F filing for Q2 2024, filed 14 Aug 2024.